Spears Abacus Advisors LLC Ventyx Biosciences, Inc. Transaction History
Spears Abacus Advisors LLC
- $4.64 Billion
- Q3 2025
A detailed history of Spears Abacus Advisors LLC transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Spears Abacus Advisors LLC holds 29,000 shares of VTYX stock, worth $268,250. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,000
Previous 29,000
-0.0%
Holding current value
$268,250
Previous $62,000
45.16%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VTYX
# of Institutions
121Shares Held
48.5MCall Options Held
152KPut Options Held
43.8K-
Black Rock Inc. New York, NY4.77MShares$44.1 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.92MShares$36.3 Million1.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.77MShares$34.9 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.21MShares$29.7 Million0.02% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$28.7 Million0.44% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $523M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...